122 related articles for article (PubMed ID: 18366183)
1. Characterization of alpha-synuclein interactions with selected aggregation-inhibiting small molecules.
Rao JN; Dua V; Ulmer TS
Biochemistry; 2008 Apr; 47(16):4651-6. PubMed ID: 18366183
[TBL] [Abstract][Full Text] [Related]
2. Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation.
Binolfi A; Lamberto GR; Duran R; Quintanar L; Bertoncini CW; Souza JM; Cerveñansky C; Zweckstetter M; Griesinger C; Fernández CO
J Am Chem Soc; 2008 Sep; 130(35):11801-12. PubMed ID: 18693689
[TBL] [Abstract][Full Text] [Related]
3. Molecular insights into the interaction between alpha-synuclein and docosahexaenoic acid.
De Franceschi G; Frare E; Bubacco L; Mammi S; Fontana A; de Laureto PP
J Mol Biol; 2009 Nov; 394(1):94-107. PubMed ID: 19747490
[TBL] [Abstract][Full Text] [Related]
4. Acceleration of alpha-synuclein aggregation by homologous peptides.
Du HN; Li HT; Zhang F; Lin XJ; Shi JH; Shi YH; Ji LN; Hu J; Lin DH; Hu HY
FEBS Lett; 2006 Jun; 580(15):3657-64. PubMed ID: 16764865
[TBL] [Abstract][Full Text] [Related]
5. On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of alpha-synuclein with Congo red and lacmoid.
Lendel C; Bertoncini CW; Cremades N; Waudby CA; Vendruscolo M; Dobson CM; Schenk D; Christodoulou J; Toth G
Biochemistry; 2009 Sep; 48(35):8322-34. PubMed ID: 19645507
[TBL] [Abstract][Full Text] [Related]
6. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein.
Heise H; Celej MS; Becker S; Riedel D; Pelah A; Kumar A; Jovin TM; Baldus M
J Mol Biol; 2008 Jul; 380(3):444-50. PubMed ID: 18539297
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric fluorescence detection of early stages in the amyloid protein aggregation of pyrene-labeled alpha-synuclein.
Thirunavukkuarasu S; Jares-Erijman EA; Jovin TM
J Mol Biol; 2008 May; 378(5):1064-73. PubMed ID: 18433772
[TBL] [Abstract][Full Text] [Related]
8. Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein.
Smith DP; Tew DJ; Hill AF; Bottomley SP; Masters CL; Barnham KJ; Cappai R
Biochemistry; 2008 Feb; 47(5):1425-34. PubMed ID: 18179253
[TBL] [Abstract][Full Text] [Related]
9. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement.
Binolfi A; Rasia RM; Bertoncini CW; Ceolin M; Zweckstetter M; Griesinger C; Jovin TM; Fernández CO
J Am Chem Soc; 2006 Aug; 128(30):9893-901. PubMed ID: 16866548
[TBL] [Abstract][Full Text] [Related]
10. DNA induces folding in alpha-synuclein: understanding the mechanism using chaperone property of osmolytes.
Hegde ML; Rao KS
Arch Biochem Biophys; 2007 Aug; 464(1):57-69. PubMed ID: 17537399
[TBL] [Abstract][Full Text] [Related]
11. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.
Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R
J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420
[TBL] [Abstract][Full Text] [Related]
12. Cu2+ binding modes of recombinant alpha-synuclein--insights from EPR spectroscopy.
Drew SC; Leong SL; Pham CL; Tew DJ; Masters CL; Miles LA; Cappai R; Barnham KJ
J Am Chem Soc; 2008 Jun; 130(24):7766-73. PubMed ID: 18494470
[TBL] [Abstract][Full Text] [Related]
13. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
14. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
[TBL] [Abstract][Full Text] [Related]
15. Fibrillogenic and non-fibrillogenic ensembles of SDS-bound human alpha-synuclein.
Ahmad MF; Ramakrishna T; Raman B; Rao ChM
J Mol Biol; 2006 Dec; 364(5):1061-72. PubMed ID: 17054982
[TBL] [Abstract][Full Text] [Related]
16. Creation of aggregation-defective α-synuclein variants by engineering the sequence connecting β-strand-forming domains.
Hernandez M; Golbert S; Zhang LG; Kim JR
Chembiochem; 2011 Nov; 12(17):2630-9. PubMed ID: 21998035
[TBL] [Abstract][Full Text] [Related]
17. Helical alpha-synuclein forms highly conductive ion channels.
Zakharov SD; Hulleman JD; Dutseva EA; Antonenko YN; Rochet JC; Cramer WA
Biochemistry; 2007 Dec; 46(50):14369-79. PubMed ID: 18031063
[TBL] [Abstract][Full Text] [Related]
18. Antiparallel arrangement of the helices of vesicle-bound alpha-synuclein.
Drescher M; Veldhuis G; van Rooijen BD; Milikisyants S; Subramaniam V; Huber M
J Am Chem Soc; 2008 Jun; 130(25):7796-7. PubMed ID: 18512917
[TBL] [Abstract][Full Text] [Related]
19. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
Kumar S; Sarkar A; Sundar D
Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781
[TBL] [Abstract][Full Text] [Related]
20. Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds.
Caruana M; Högen T; Levin J; Hillmer A; Giese A; Vassallo N
FEBS Lett; 2011 Apr; 585(8):1113-20. PubMed ID: 21443877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
